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Mitochondrial  ferritin  (FtMt)  is a novel  protein  encoded  by an  intronless  gene  mapped  to  chromosome
5q23.1.  Ferritin  is  ubiquitously  expressed;  however,  FtMt  expression  is restricted  to  speciﬁc  tissues  such
as  the  testis  and  the  brain.  The  distribution  pattern  of FtMt  suggests  a functional  role  for  this  protein  in
the  brain;  however,  data  concerning  the roles  of  FtMt  in  neurodegenerative  diseases  remain  scarce.  In
the  human  cerebral  cortex,  FtMt  expression  was  increased  in  Alzheimer’s  disease  patients  compared  to
control  cases.  Cultured  neuroblastoma  cells  showed  low-level  expression  of  FtMt,  which  was  increased
by  H2O2 treatment.  FtMt  overexpression  showed  a neuroprotective  effect  against  H2O2-induced  oxida-
tive  stress  and  A-induced  neurotoxicity  in  neuroblastoma  cells.  FtMt  expression  was  also  detected  in
dopaminergic  neurons  in the  substantia  nigra  and was  increased  in  patients  with  restless  legs  syndrome,ubstantia nigra
xidative  stress
while  FtMt  had  a protective  effect  against  cell death  in  a neuroblastoma  cell  line  model  of  Parkinson’s
disease.  FtMt  is involved  in other  neurodegenerative  diseases  such  as age-related  macular  degeneration
(AMD),  with  an  FtMt  gene  mutation  identiﬁed  in  AMD patients,  and  Friedreich’s  ataxia,  which  is caused
by  a  deﬁciency  in frataxin.  FtMt overexpression  in  frataxin-deﬁcient  cells  increased  cell  resistance  to
H2O2 damage.  These  results  implicate  a neuroprotective  role  of  FtMt  in  neurodegenerative  diseases.
©  2013  The  Authors.  Published  by  Elsevier  Ireland  Ltd and the  Japan  Neuroscience  Society. ontents
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. Introduction Nascimento et al., 2012; Kell, 2010; LeVine, 1997; Sian-Hulsmann
et al., 2011; Zecca et al., 2004). Free iron is a source of oxidative
Open access under CC BY-NC-SA license.Iron is the most abundant transition metal in the brain, and
ts concentration increases with aging (Connor et al., 1990; Zecca
t al., 2004) as well as in neurodegenerative diseases such as
lzheimer’s disease (AD) and Parkinson’s disease (PD) (Batista-
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ttp://dx.doi.org/10.1016/j.neures.2013.07.005stress and subsequent cell damage; therefore, under physiologi-
cal conditions, iron is normally bound to proteins such as ferritin
and transferrin (Connor et al., 1990, 1992). Indeed, the presence
of excessive free iron is a hallmark of aging diseases because it is
not correctly stored in ferritin cores such as the ferric iron oxide
redox-inert form (Altamura and Muckenthaler, 2009; Casadesus
et al., 2004; Huang et al., 2004; Smith et al., 1997). Although excess
iron is stored primarily in the cytoplasm, most of the metabolically
active iron in cells is processed in the mitochondria.
Mitochondrial ferritin (FtMt) is a novel protein encoded by an
intronless gene mapped to chromosome 5q23.1 (Levi et al., 2001).
ence Society. Open access under CC BY-NC-SA license.
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Fig. 1. Iron metabolism in neurons. Transferrin binds Fe(III) to form trans-
ferrin/transferrin receptor complexes, which are endocytosed into cell via the
invagination of clathrin-coated pits. In the acidic endosome, Fe(III) is reduced to
Fe(II) by Steap 3 and transported by DMT1 to labile iron pool (LIP) in the cytoplasm,
where Fe(II) is stored in ferritin or imported into mitochondria by mitoferrin. Non-
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expressing mouse FtMt had increased mitochondrial iron andransferrin-bound Fe(II) at the cell surface is imported directly into the LIP by DMT1
n  the cell surface.
he FtMt 242-amino acid precursor protein has a predicted molec-
lar weight of 30 kDa and 79% homology to H-chain ferritin. This
recursor protein has a positively charged leader sequence of 60
mino acids and is imported into the mitochondria where it is
roteolytically cleaved to a ∼22-kDa mature protein. The cleaved
tMt forms H-type ferritin shells with ferroxidase activity that most
ikely sequesters potentially harmful free iron (Corsi et al., 2002;
rysdale et al., 2002; Levi and Arosio, 2004).
Ferritin composed of H-type and L-type subunits is widely dis-
ributed in the body. However, FtMt gene expression is low in
ron-storage organs such as the liver and spleen but can be detected
n speciﬁc tissues such as the testis, kidney, heart, thymus, and brain
Campanella et al., 2004; Drysdale et al., 2002; Hahn et al., 2004).
his distribution pattern suggests that FtMt plays a functional role
n these tissues, including the brain; however, little information is
urrently available regarding the roles of FtMt in neurodegenera-
ive diseases.
This paper aims to review recent research regarding FtMt
unctions in neurodegenerative diseases such as AD. An under-
tanding of the various roles of FtMt may  provide new insight
nto pathogenic mechanisms and therapeutic strategies for AD and
ther neurodegenerative diseases.
. Iron metabolism in the brain
First, we summarize iron metabolism in the brain. Fig. 1 illus-
rates the mechanisms of iron metabolism and iron regulatory
roteins in neurons, and Table 1 summarizes the distributions, sub-
ellular localizations and iron regulation functions of iron-related
roteins.
Iron in serum is bound to iron transport proteins such as trans-
errin and lactotransferrin. Transferrin binds two atoms of Fe(III)
halo-transferrin), and two  halo-transferrin molecules bind to one
ransferrin receptor molecule on the plasma membrane of cells.
he halo-transferrin/transferrin receptor complex becomes incor-
orated into a clathrin-coated pit, which invaginates and is then
ndocytosed to fuse with an endosome (Fig. 1). Another pathway
f iron uptake is through the divalent metal iron transporter 1esearch 77 (2013) 1–7
(DMT1), which only binds ferrous iron Fe(II). Therefore, Fe(III) has
to be reduced prior to cell entry via DMT1 (Garrick, 2011).
In the brain, iron must be transported from the serum through
the blood brain barrier (BBB). Endothelial cells in the brain capillary
and choroid plexus cells express transferrin receptors (Giometto
et al., 1990; Moos, 1996; Moos et al., 1998; Rothenberger et al.,
1996), while lactoferrin receptors are present in brain capillaries,
neurons, and several glial cells (Faucheux et al., 1995). Lacto-
transferrin may  also play a role in iron transport at the BBB
(Fillebeen et al., 1999), and brain capillaries express the low-density
lipoprotein-related protein (LRP), which is a receptor for lacto-
transferrin (Tooyama et al., 1993, 1995) and other ligands such
as 2-macroglobulin, apolipoprotein E (ApoE), amyloid precur-
sor protein (APP), plasminogen activators, plasminogen activator
inhibitor I (PAI-1), lipoprotein lipase, receptor-associated pro-
tein (RAP), interleukin-1,  transforming growth factor (TGF)-,
platelet-derived growth factor (PDGF), and ﬁbroblast growth factor
(FGF) (Rebeck et al., 1993). These ligands are taken up by cells via
receptor-mediated endocytosis.
The sites of DMT1 expression remain controversial. Burdo et al.
(2001) demonstrated the presence of DMT1 in brain capillaries
(Burdo et al., 2001); however, Moos and his colleagues reported
that brain capillary endothelial cells do not express DMT1 (Moos
and Morgan, 2004; Moos et al., 2006). The latter authors also sug-
gested that iron passes through the BBB without the involvement of
DMT1 (Moos et al., 2006), and they noted the importance of inter-
actions between endothelial cells and astrocytes in the BBB transit
of iron (Moos et al., 2007). Low molecular-weight molecules such
as ATP and citrates help to mediate the release of iron from trans-
ferrin into the brain extracellular ﬂuid (Crichton et al., 2011; Moos
and Morgan, 1998).
As shown in Table 1, ferritin (Connor et al., 1990, 1992; Han
et al., 2002) and transferrin (Dwork et al., 1988; Connor et al., 1990,
1992) have been shown to be present in neurons and glia. Neurons
also express transferrin receptors and take up transferrin-bound
iron into the endosome by receptor-mediated endocytosis (Dwork
et al., 1988). In the acidic endosome, Fe(III) is released from pro-
teins and reduced to Fe(II) by Steap 3, a member of the Steap family
of metalloreductases (Ohgami et al., 2006). Fe(II) in the cytoplasm
transiently enters the labile iron pool (LIP) where iron is bound
to low-molecular-mass intracellular chelates such as citrate, vari-
ous peptides, ATP, AMP, and pyrophosphate. Neurons also express
DMT1 and absorb iron in the cytoplasm, with excess ferrous iron
exported from the cytoplasm by ferroportin in the cell membrane
(Moos et al., 2007).
Cells primarily use the iron located in mitochondria for the
synthesis of heme and iron–sulfur clusters, and the entry of iron
into mitochondria requires the solute carrier (SLC) transporter,
mitoferrin (Richardson et al., 2010). As a ubiquitous protein, the
ATP-binding cassette transporter ABCB7 may  also be involved in
iron export from the mitochondria to the cytosol, and a deﬁciency
in this transporter potentially causes mitochondrial iron accumu-
lation (Cavadini et al., 2007). Cells also store and detoxify excess
intracellular iron in the cytoplasm within ferritin composed of
H- and L-subunits. H-ferritin possesses ferroxidase activity, and
L-ferritin provides a nucleation center (Fig. 1).
Mitochondria contain another type of ferritin, FtMt, which also
possesses ferroxidase activity. FtMt overexpressed in HeLa cells
was translocated into mitochondria and incorporated with iron
(Corsi et al., 2002), and simultaneously, cytosolic ferritin levels
decreased and transferrin receptor levels increased (Corsi et al.,
2002). Nie et al.  (2005) also reported that a stable cell line over-decreased cytosolic iron together with increased transferrin recep-
tor levels and decreased cytosolic ferritin (Nie  et al., 2005). These
results suggest that FtMt together with cytosolic ferritin and the
H. Yang et al. / Neuroscience Research 77 (2013) 1–7 3
Table  1
Distribution, subcellular localization, and iron-regulatory functions of some iron-related proteins in the brain.
Distribution in brain Subcellular
localization
Iron regulation References
Ferritin Neuron, Glia Cytoplasm Iron storage; Ferroxidase activity Connor et al. (1990, 1992) and Han et al. (2002)
FtMt Neuron, Glia Mitochondria Iron storage; Ferroxidase activity Drysdale et al. (2002), Santambrogio et al. (2007) and
Wang et al. (2011)
Transferrin Neuron, Glia, Choroid
plexus
Cytoplasm Iron binding and transport Dwork et al. (1988) and Connor et al. (1990, 1992)
Transferrin R Neuron, Capillary,
Choroid plexus
Membrane Receptor-mediated endocytosis
and exocytosis
Giometto et al. (1990), Moos (1996), Moos et al.
(1998) and Rothenberger et al. (1996)
Lactoferrin Neuron, Microglia Cytoplasm Iron binding and transport Kawamata et al. (1993), Leveugle et al. (1994) and An
et  al. (2009)
Lactoferrin R
(and LRP)
Neuron, Glia, Capillary Membrane Receptor-mediated endocytosis Faucheux et al. (1995) and Tooyama et al. (1993,
1995)
DMT1 Neuron, Capillary? Membrane Internalization of iron Burdo et al. (2001)
Ferroportin Neuron Membrane Iron exporting carrier Moos et al. (2007)
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in neurodegeneration (Fig. 2), and the mitochondrion is one of the
main organelles where such an autotoxic loop may  occur because
of the role mitochondria play in iron utilization.
Fig. 2. An autotoxic loop may  occur in the brain of AD sufferers. Ferrous iron gen-
erates oxidative stress by producing reactive oxygen species (ROS) via Fenton and
Haber–Weiss reactions. High cellular iron upregulates the expression of amyloidMitoferrin Neuron? Mitochondria Transpor
tMt, mitochondrial ferritin; R, receptor; LRP, low-density lipoprotein-related prote
ransferrin receptor cooperatively regulate iron homeostasis in
oth the cytoplasm and in mitochondria.
In the mouse brain, FtMt is expressed primarily in neurons
Santambrogio et al., 2007; Snyder et al., 2010) and to a lesser
xtent in glial cells (Snyder et al., 2010). The neuronal expression
f FtMt is supported by other studies using human brain tissues
Snyder et al., 2009; Wang et al., 2011). As described above, FtMt
as restricted tissue expression compared with cytosolic ferritin,
hich is ubiquitously expressed. Additionally, unlike cytosolic fer-
itin, FtMt is not regulated by iron-dependent translational control
ecause the FtMt gene lacks the classical stem-loop iron-regulatory
lement (Drysdale et al., 2002). The unique distribution pattern of
itochondrial ferritin suggests that FtMt expression may  be reg-
lated at the transcriptional level by tissue- and cell type-speciﬁc
ranscription factors.
Excessive iron in speciﬁc brain cellular constituents, includ-
ng mitochondria, leads to the generation of toxic free radicals,
esulting in cell damage that eventually causes neurodegenera-
ive diseases (Ames et al., 1993; Crichton et al., 2011; Crichton and
ard, 2006; Honda et al., 2004; Huang et al., 2004). Speciﬁcally,
e(II) reacts with hydrogen peroxide (H2O2) via the Fenton reaction
o generate reactive and harmful hydroxyl radicals (OH•) (Goldstein
t al., 1993; Winterbourn, 1995; Winterbourn et al., 2002); how-
ver, superoxide (O2−) reacts with Fe(III) in the Haber–Weiss
eaction to regenerate Fe(II) (Kehrer, 2000), causing a redox cycling
f the iron.
. Mitochondrial ferritin in AD
Iron accumulation and oxidative stress in the brains of AD suf-
erers have been correlated with AD progression (Altamura and
uckenthaler, 2009; Bartzokis et al., 2000; Casadesus et al., 2004;
richton et al., 2011; Deibel et al., 1996; Honda et al., 2004, 2005;
uang et al., 2004; Kell, 2010; LeVine, 1997). In addition, abnor-
alities in iron-regulating proteins, including transferrin (Connor
t al., 1992), melanotransferrin (Jefferies et al., 1996; Yamada et al.,
999), lactotransferrin (An et al., 2009; Kawamata et al., 1993), iron
egulatory proteins (IRPs) (Pinero et al., 2000; Smith et al., 1998),
nd ferritin (Connor et al., 1992) occur in the brain of AD sufferers.
Experimental evidence suggests an interaction between iron
nd amyloid beta-protein (A)  metabolism in the brain. Iron accu-
ulation occurs in the same regions of the brain characterized by
 deposition (Huang et al., 2004; LeVine, 1997), and A binds
ron directly in vitro (Exley, 2006; Jiang et al., 2009). The level
f intracellular APP is also tightly regulated by iron via the bind-
ng of iron directly to the APP 5′-UTR, which governs the rate of
PP translation. The expression of APP is upregulated by increasedon into mitochondria Richardson et al. (2010)
T1, divalent metal iron transporter.
iron; however, it is repressed by iron chelation (Rogers et al., 2002).
Furin is an enzyme belonging to the subtilisin-like proprotein con-
vertase family and has been linked to iron homeostasis and A
production (Crichton et al., 2011). Low and high cellular iron levels
increase and decrease the activity of furin, respectively. In turn,
furin enhances -secretase to stimulate the non-amyloidogenic
pathway. Therefore, high cellular iron induces the reduction of furin
activity and subsequent A production (Silvestri and Camaschella,
2008; Silvestri et al., 2008). In the brains of AD patients and Tg2576
mice, furin mRNA levels were signiﬁcantly lower compared to the
levels in the controls (Hwang et al., 2006), which is consistent with
the different iron accumulation patterns in AD patients and con-
trols. A is a potent generator of reactive oxygen species (Hensley
et al., 1994) and reactive nitrogen species (Combs et al., 2001), and
in turn, oxidative stress promotes intracellular accumulation and
production of A (Misonou et al., 2000; Silvestri and Camaschella,
2008).
Overall, excess iron may  induce an autotoxic loop that resultsprecursor protein, which activates the amyloidogenic pathway, leading to increased
A production (Silvestri and Camaschella, 2008; Silvestri et al., 2008). A is neuro-
toxic to the brain via the induction of ROS production (Hensley et al., 1994), and
oxidative stress promotes further intracellular accumulation and production of A
(Misonou et al., 2000; Silvestri and Camaschella, 2008).
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Fig. 3. Expression levels of FtMt mRNA (A) and protein (B) in the cerebral cortex of AD patients and control cases. (A) Expression in the temporal cortex of AD patients (n = 5)
is  signiﬁcantly higher compared to control cases (n = 5). To correct for mRNA variability, the amount of FtMt mRNA obtained from each sample was divided by the amount
of  -actin mRNA. The relative value was  calculated with the following formula: (FtMt mRNA)/(-actin mRNA) × 105. An asterisk indicates signiﬁcant difference from the
control (*P < 0.05; **P < 0.01). (B) The expression level of FtMt protein in the temporal cortex of AD patients is higher compared to the level in the control cases. Proteins
(50  g per lane) from the temporal cortex of an AD and a control case were electrophoresed on 15% SDS-polyacrylamide gels and were then transferred to a polyvinylidene
diﬂuoride membrane (Immobilon-P, Nippon Millipore Ltd., Tokyo, Japan). We used the anti-FtMt rabbit polyclonal antibody at 1:1000 (A93251Hu, Uscn, Wuhan, China) and
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pCL  Western blotting detection reagents (SuperSignal West Pico, Thermo Scientiﬁc
FtMt plays a profound role in regulating iron homeostasis and
xidative stress; therefore, it may  participate in both the patho-
enesis and the pathological progression of AD. However, limited
ata are available regarding the relationship between FtMt and AD.
e recently demonstrated by in situ hybridization that the FtMt
ene was primarily expressed in neurons located in the temporal
ortex in both AD patients and normal individuals (Wang et al.,
011), although this expression was greater in the AD sufferers
Fig. 3). These observations support the possible involvement of
tMt in AD pathogenesis.
Increased expression of FtMt was induced by H2O2 in the human
euroblastoma IMR-32 cell line (Fig. 4). Interestingly, this induc-
ion occurred when H2O2 was used in combination with A1–42
ut not with A1–42 alone (Wang et al., 2011). The treatment of
euroblastoma cells with H2O2 in combination with A is likely
o induce intense oxidative stress. Indeed, the increased level of
xidative stress observed in the brains of AD sufferers may  reﬂect similar induction of FtMt expression in the cortex. The result is
lso consistent with animal experiments suggesting that A alone
s insufﬁcient to induce AD-like symptoms due to the antioxidant
efense activity present in the brain. A-independent oxidative
ig. 4. FtMt mRNA (A) and protein (B) expression levels in cultured cells. Compared to th
igniﬁcantly induced after H2O2 treatment. IMR-32 cells were seeded in 60-mm dishes a
ells  were incubated for 30 min. Medium was replaced with fresh medium. Total protein
NA  solution was treated with DNase to eliminate contaminating DNA. The FtMt mRNA (
robes and Western blotting, respectively.ford, IL, USA).
stress reduces the effectiveness of this antioxidant defense system,
which allows the A peptide to induce AD-like symptoms (Lecanu
et al., 2006).
FtMt expression is normally low in neuroblastoma cell lines but
is stimulated by oxidative stress (Wang et al., 2011). The overex-
pression of FtMt in IMR-32 cells protected these cells from neuronal
death induced by H2O2 (Fig. 5) and A25–35 (Wu et al., 2013). In turn,
knockdown of FtMt signiﬁcantly enhanced A25–35-induced neuro-
toxicity by dysregulation of iron homeostasis, enhanced oxidative
stress, and increased cell apoptosis (Wu et al., 2013). These data
indicate that FtMt is induced under pathological conditions associ-
ated with mitochondrial iron loading or oxidative stress and may
play a neuroprotective role against oxidative stress and A neu-
rotoxicity. Although increased endogenous FtMt expression occurs
upon incubation with H2O2, we  were not able to rescue cell via-
bility unless FtMt was expressed prior to H2O2 treatment (Wang
et al., 2011). One explanation for this observation is that exogenous
H2O2-induced cell death occurs before FtMt exerts its neuropro-
tective effect. Therefore, it appears that the overexpression of FtMt
prior to cell treatment with H2O2 has a greater protective effect
than endogenous FtMt expression.
e untreated control, the FtMt mRNA (***P < 0.001) and protein expression levels are
t a density of 500,000 and grown for 48 h. Next, 200 M H2O2 was added, and the
 and RNA was  extracted from 6 independent dishes after an 18-h recovery period.
A) and protein (B) expression levels were detected by real-time PCR using TaqMan
H. Yang et al. / Neuroscience R
Fig. 5. The effect of FtMt expression on cell viability after H2O2 treatment. The over-
expression of FtMt in IMR-32 cells increased cell viability compared to wild-type
cells (**P < 0.01) and empty vector-transfected cells (***P < 0.001). IMR-32 cells were
seeded in 96-well plates at a density of 10,000 cells and grown for 24 h, and then
the  cells were transiently transfected with either an FtMt expression plasmid or an
empty vector. At 24 h post-transfection, cells were treated with or without 300 M
H2O2 for 30 min, and then the cells were recovered for 18 h in fresh medium. Cell via-
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the occurrence of selected disorders such as RLS. Improved under-ility was measured using the MTT  assay. The data are expressed as the percentage
f  untreated cells (n = 8) ± standard deviation in each group.
. Mitochondrial ferritin in PD and restless legs syndrome
RLS)
PD has many features in common with syndromes associated
ith the disruption of iron homeostasis, mitochondria dysfunc-
ions, and oxidative stress (Lin and Beal, 2006; Sian-Hulsmann et al.,
011; Zhang et al., 2000). Iron concentrations in the substantia nigra
nd globus pallidus are higher than the levels in other brain regions.
D brains show increased levels of iron (Gotz et al., 2004; Dexter
t al., 1987), which was found to accumulate within Lewy bod-
es, which are the characteristic hallmarks of PD (Castellani et al.,
000). Studies have also shown that iron promotes the aggregation
f -synuclein, which is the primary component of Lewy bodies,
hile the aggregation of -synuclein is blocked by iron chelation
Ostrerova-Golts et al., 2000; Sangchot et al., 2002).
The neuroblastoma SH-SY5Y cell line model of PD is induced by
-hydroxydopamine (6-OHDA), a neurotoxin that causes selective
eath in catecholamine-containing neurons. The overexpression
f FtMt signiﬁcantly prevented the alteration of iron redistribu-
ion and caused cytosolic iron deﬁciency in the SH-SY5Y cell line
odel of PD (Shi et al., 2010). FtMt also strongly decreased pro-
uction of reactive oxygen species and lipid peroxidation as well
s repressed the loss of mitochondrial membrane potential. More-
ver, FtMt expression regulates apoptotic signaling by increasing
he level of anti-apoptotic protein, Bcl-2, which prevents caspase-
 activation, eventually rescuing the neuronal cells (Shi et al.,
010).
RLS is associated with the urge to move legs accompanied by
bnormal sensations in the legs, particularly at rest. Transcranial
ltrasounds (Schmidauer et al., 2005) and magnetic resonance
maging (MRI) (Allen et al., 2001) demonstrated decreased iron
evels in the substantia nigra of patients with RLS; however, a
europathological study of postmortem human brains revealed
ncreased FtMt and decreased H-ferritin in the substantia nigra
f these patients (Snyder et al., 2009). The overexpression of FtMt
ecreases cytosolic iron levels (Corsi et al., 2002; Nie et al., 2005);
herefore, Snyder et al. (2009) suggested that FtMt may  contribute
o the reduced cytosolic iron levels in the substantia nigra neurons
f patients with RLS (Snyder et al., 2009).Thus far, FtMt studies suggest that the increased expression of
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oxidative stress via iron sequestration. In contrast, in RLS, increased
FtMt expression may  be linked to disease occurrence rather than
neuroprotection. Nevertheless, these interesting ﬁndings implicate
FtMt in the pathogenesis of neurological diseases. In addition, stud-
ies into the mechanism by which FtMt expression is regulated
should be prioritized because, unlike other ferritins, FtMt lacks
iron-responsive elements in its mRNA and is not regulated directly
by iron.
5. Mitochondrial ferritin in other diseases
Iron accumulation with age contributes to the pathogenesis of
age-related macular degeneration (AMD) by inducing considerable
oxidative stress (He et al., 2007). Postmortem studies showed an
increased total iron level in AMD-affected maculas compared to
healthy maculas, and a portion of this iron was chelatable; there-
fore, iron chelation may  be a potential therapy for AMD  (Hahn et al.,
2003). Immunohistochemistry demonstrated that FtMt localizes
to the inner segments of the retinas and showed increased FtMt
with iron accumulation (Hahn et al., 2004). An FtMt gene muta-
tion was also identiﬁed in patients affected by AMD, suggesting
that dysfunctional FtMt may  be associated with AMD  pathogene-
sis via reduced protection from iron-dependent oxidative stress in
mitochondria (Stenirri et al., 2012).
High-level FtMt expression is also associated with the iron-
loaded erythroblasts in patients with sideroblastic anemia but
is not observed in normal erythroblasts (Cazzola et al., 2003).
Sideroblastic anemia is a disorder characterized by mitochondrial
iron overload and high levels of FtMt expression exclusively in
ringed sideroblasts. FtMt has been proposed to protect the mito-
chondria from damage caused by iron loading in this disease
(Cazzola and Invernizzi, 2011; Cazzola et al., 2003; Napier et al.,
2005).
Friedreich’s ataxia (FRDA) is a disorder characterized by mito-
chondrial iron overload caused by a deﬁciency of frataxin, which
is a mitochondrial protein involved in iron handling. Human FtMt
expression in frataxin-deﬁcient yeast cells prevented the devel-
opment of mitochondrial iron overload, preserved mitochondrial
DNA integrity, and increased cell resistance to H2O2 (Campanella
et al., 2004). Similarly, the effects of silencing frataxin expres-
sion in HeLa cells were rescued by inducing the expression of
human FtMt, which indicates a protective role of FtMt in mito-
chondrial iron-loaded cells (Campanella et al., 2009; Zanella et al.,
2008).
6. Conclusions
FtMt is a novel protein localized in mitochondria. FtMt is
expressed in restricted tissues including the brain. FtMt lacks iron
regulatory elements, and its expression is increased by oxidative
stress. The unique distribution and stress-inducing property of its
expression suggest that FtMt may  play an important physiologi-
cal and pathological role in the brain. Iron and oxidative stresses
are strongly correlated with numerous neurological diseases, not
only those mentioned in this review, indicating that FtMt may  be
involved in the pathogenesis of a range of diseases. However, infor-
mation concerning the role of FtMt in neurological pathology is still
limited. FtMt is increased in the cerebral cortex of AD patients and in
the substantia nigra of individuals with PD and RLS. The presence of
FtMt prevents cell death induced by oxidative stress and neurotoxic
proteins, although under some circumstances, FtMt is linked tostanding of the role of FtMt may  therefore provide new insights
into the pathogenesis and therapeutic strategies for AD and other
neurodegenerative diseases.
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